Table 1.
Summary of the clinical study of fucosylated haptoglobin as a cancer biomarker
| Methods | Patient number | AUC | Sensitivity, % | Specificity, % | Reference |
|---|---|---|---|---|---|
| AAL lectin blot | PC 49, HV 30 | − | 57 | 97 | 17 |
| AAL lectin–antibody ELISA | PC 63, HV 22 | 0.63 | 50 | 91 | 21 |
| AAL lectin–antibody ELISA | PC 63, CP 72 | 0.63 | 50 | 79 | 21 |
| Improved AAL lectin–antibody ELISA | PC 300, HV 315 | 0.91 | 85 | 82 | 20 |
| PhoSL lectin–antibody ELISA | PC 55, HV 60 | 0.68 | 60 | 83 | 36 |
| Improved AAL lectin–antibody ELISA | PC 83, HV 59 | 0.84 | 76 | 80 | 37 |
| Improved AAL lectin–antibody ELISA | PC 83, CP 159 | 0.65 | 52 | 78 | 37 |
| Improved PhoSL lectin–antibody ELISA | PC 83, HV 59 | 0.63 | 41 | 85 | 37 |
| Improved PhoSL lectin–antibody ELISA | PC 83, CP 159 | 0.81 | 69 | 84 | 37 |
AAL, Aleuria aurantia lectin; CP chronic pancreatitis; HV, healthy volunteers; PC, pancreatic cancer; PhoSL, Pholiota squarrosa lectin.